Several lactic acid bacterial (LAB) strains have probiotic properties. A crucial requirement for probiotics to benefit the host’s health is their ability to adhere to the intestinal lining enriched with glycosylated mucins. Many intestinal diseases display marked changes in mucin glycosylation such as reduced sialylation and fucosylation. Such alterations have been shown to allow for the lesser adhesion of the probiotic bacteria in vitro. Although probiotics are often used in intestinal diseases, this phenomenon might reduce their in vivo intestinal adhesion, which could be a reason for the ineffectiveness of some probiotics in such conditions as reported in a few studies. Adaptive laboratory evolution (ALE) offers an intuitive way of improving bacterial properties without performing deliberate genetic modifications. In this paper, it is hypothesized that probiotic strains with enhanced adhesion to the mucin altered in intestinal diseases would be better candidates to alleviate the symptoms of these diseases, and such strains can be created through ALE. This hypothesis is supported by a few earlier studies showing the ability of certain other bacteria to mutate themselves to enhance their adhesion to biotic and abiotic environments. The steps involved in testing the hypothesis would be improving the in vitro adhesion of lactobacilli to the intestinal mucus obtained from patients with intestinal diseases by daily adhesion and passaging of the adherent bacteria for several weeks. The improved strains can be subjected to animal studies and human clinical trials in the second part. Since some commensals make short-chain fatty acids from dietary fiber, which stimulate mucin production by the intestinal cells, the clinical trials can be performed under a dietary regime. Apart from providing novel probiotic candidates, such a study can also reveal yet the novel mechanism of adhesion of probiotics to the intestinal environment.
Read full abstract